Evidence map›Paper›PMID 42769966›Full record

ReviewFrontiers in immunology2026

The hidden threat: understanding anti-PF4 disorders without proximate heparin exposure.

Zhiyan Liu, Yan Li, Liang Ma, Xin Wang, Yimin Cui

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhiyan LiuInstitute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Yan LiDepartment of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Liang MaDepartment of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Xin WangClinical Trial Research Center, Beijing Hospital, Beijing, China.
Yimin CuiInstitute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparin-induced thrombocytopenia (HIT) is now recognized as one subset of a broader group of disorders: anti-platelet factor 4 (anti-PF4) disorders. This review provides an updated framework for anti-PF4 immunothrombosis without proximate heparin exposure-a clinical syndrome with phenotypic and laboratory features resembling classic HIT but with no recent heparin use (no heparin exposure within 14 days before onset). The core characteristics are a ≥50% platelet count decrease from baseline or an absolute platelet count <100×10

Indexed as

AnticoagulantsAutoantibodiesHeparinPlatelet Factor 4ThrombocytopeniaAnimalsHumansAnticoagulantsAutoantibodiesHeparinPF4 protein, humanPlatelet Factor 4anti-PF4 disordersheparinHITplatelet factor 4thrombosis

Identifiers

PMID42769966
PMCPMC13591625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.